Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Endocrinology
•
Bone and Calcium Disorders
Does parathyroidectomy for primary hyperparathyroidism provide metabolic benefits, such as lowering diabetes or cardiovascular disease risk?
Related Questions
When interpreting a 24-hour urinary calcium, which is more accurate: 24 hour urine calcium (mg/day) or 24-hour calcium-to-creatinine ratio (mg/g)?
In asymptomatic patients with mild CKD, PTH independent hypercalcemia, and hypercalciuria—after excluding common causes such as hyperparathyroidism, vitamin D abnormalities, multiple myeloma, thyroid disease, vitamin A excess, and antacid use—what is the next best step in evaluation?
What patient factors are most important when considering who needs a broader workup for osteoporosis prior to starting therapy? If you workup all patients, what labs do you find most helpful to start with?
How do you counsel patients on the risks and benefits of strontium supplements for osteoporosis management?
What are some practical tips in distinguishing between metabolic bone disease due to chronic kidney disease and osteoporosis?
What can cause a vertebra to be hyperdense on bone density testing and thus excluded other than vertebral fracture or degenerative change?
Is there any data on denosumab use beyond 10 years from the FREEDOM Extension trial, and what do we know about the risk of atypical femoral fracture and osteonecrosis of the jaw after 10 years?
What is the optimal management of pain and loss of function due to pathologic compression fractures?
Would you have concerns with continuing denosumab for much longer than the available ten year clinical safety trial data for an individual with renal insufficiency with persistent osteoporosis/history of compression fractures?
Should we aim to reduce or stop thiazides in patients with thiazide-induced hypercalcemia given its similar risk profile to untreated primary hyperparathyroidism?
